Issue 29, 2022

In vitro and ex vivo nano-enabled immunomodulation by the protein corona

Abstract

New technologies with the capacity to tune immune system activity are highly desired in clinical practice and disease management. Here we demonstrate that nanoparticles with a protein corona enriched with gelsolin (GSN), an abundant plasma protein that acts as a modulator of immune responses, are avidly captured by human monocytic THP-1 cells in vitro and by leukocyte subpopulations derived from healthy donors ex vivo. In human monocytes, GSN modulates the production of tumor necrosis factor alpha (TNF-α) in an inverse dose-dependent manner. Overall, our results suggest that artificial coronas can be exploited to finely tune the immune response, opening new approaches for the prevention and treatment of diseases.

Graphical abstract: In vitro and ex vivo nano-enabled immunomodulation by the protein corona

Supplementary files

Article information

Article type
Paper
Submitted
05 Apr 2022
Accepted
01 Jul 2022
First published
05 Jul 2022

Nanoscale, 2022,14, 10531-10539

In vitro and ex vivo nano-enabled immunomodulation by the protein corona

F. Giulimondi, L. Digiacomo, E. Vulpis, L. Loconte, G. Ferri, F. Cardarelli, D. Pozzi, A. Zingoni and G. Caracciolo, Nanoscale, 2022, 14, 10531 DOI: 10.1039/D2NR01878K

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements